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able for the detection of occult paroxysmal atrial ﬁbrillation (AF) after stroke; however, most
studies involved patients aged≥ 65 years— a population with a high stroke rate.
Aims.— To assess the incidence of paroxysmal AF in unselected young patients presenting with
stroke.
Abbreviations: AF, Atrial ﬁbrillation; CI, Conﬁdence interval; CS, Cryptogenic stroke; ECG, Electrocardiogram; MRI, Magnetic resonance
imaging; SKC, Stroke of known cause; TIA, Transient ischaemic attack.
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Methods.— We included consecutive patients aged < 60 years with a stroke diagnosis on mag-
netic resonance imaging. Aetiological screening included clinical history and examination, and
biological and cardiac tests. Patients were included if they had no history of AF and if a 24-hour
electrocardiogram recording detected no AF or atrial ﬂutter. Patients wore the SpiderFlash®
monitor for 21 days after discharge from hospital. The primary outcome was detection of parox-
ysmal AF episodes lasting > 30 seconds during monitoring. The secondary outcome was detection
of paroxysmal AF episodes lasting < 30 seconds and any arrhythmia during monitoring.
Results.— Among the 56 patients included (mean age 48± 9 years), 39 had cryptogenic stroke
(CS) and 17 had stroke of known cause (SKC). Cardiac monitoring was achieved in 54 patients (37
CS, 17 SKC); one CS patient had a paroxysmal AF episode lasting > 30 seconds and one CS patient
had a paroxysmal AF episode lasting < 30 seconds (versus no patients in the SKC group). Two CS
patients and one SKC patient presented numerous premature atrial complexes. Non-sustained
ventricular tachycardia was detected in one CS patient.
Conclusion.— This prospective observational study showed a low rate of paroxysmal AF among
young patients presenting with stroke, on the basis of 21-day cardiac monitoring. This result
highlights the need to identify patients who would beneﬁt from such long monitoring.
© 2015 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— De nombreuses études ont suggéré qu’une durée plus étendue d’enregistrement
électrocardiographique améliorait le taux de détection de la ﬁbrillation auriculaire (FA) parox-
ystique occulte après un accident vasculaire cérébral (AVC) ischémique, mais la plupart de
ces études ont porté sur les patients≥ 65 ans d’âge—une population avec un taux élevé d’AVC
ischémique.
Objectif.— Évaluer l’incidence de la FA paroxystique chez les patients jeunes présentant un
AVC ischémique.
Méthodes.— Nous avons inclus de manière consécutive des patients âgés de 18 à 60 ans avec un
diagnostic d’AVC ischémique à l’imagerie par résonance magnétique. Les explorations à visée
étiologique ont inclus l’anamnèse, l’examen clinique et des tests biologiques et cardiaques.
Les patients ont été inclus s’ils n’avaient pas d’antécédent de FA et si un enregistrement
de l’électrocardiogramme des 24 heures n’a détecté aucune FA ou ﬂutter auriculaire. Après
la sortie de l’hôpital, les patients ont porté le moniteur SpiderFlash® pendant 21 jours. Le
critère principal de jugement était la détection d’épisodes de FA paroxystique > 30 secondes
pendant la surveillance. Les critères secondaires étaient la détection d’épisodes de FA parox-
ystique < 30 secondes ou de toute autre arythmie.
Résultats.— Parmi les 56 patients inclus (âge moyen 48± 9 ans), 39 avaient un AVC cryp-
togénique (CS) et 17 un AVC de cause connue (SKC). L’enregistrement de 21 jours a été obtenu
chez 54 patients (37 CS, 17 SKC) ; un patient dans le groupe des CS a présenté des épisodes
de FA paroxystique > 30 secondes et un patient avec un CS a eu un épisode de FA paroxys-
tique < 30 secondes (contre aucun patient dans le groupe SKC). Deux patients dans le groupe
des CS et un patient avec un SKC ont présenté de nombreuses extrasystoles auriculaires. Un
épisode de tachycardie ventriculaire non soutenue a été détecté chez un patient ayant un CS.
Conclusion.— Cette étude observationnelle prospective a montré un faible taux de FA parox-
ystique chez les jeunes patients présentant un AVC ischémique, après un enregistrement de
21 jours. Ce résultat met en évidence la nécessité de sélectionner les patients qui pourraient
bénéﬁcier de ce suivi électrocardiographique prolongé.
© 2015 Elsevier Masson SAS. Tous droits réservés.
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cackgroundtrial ﬁbrillation (AF) is the cause of 20—25% of all
schaemic strokes, which are more severe and associated
ith higher mortality rates than strokes resulting from other
d
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oauses [1]. Oral anticoagulation is recommended in patients
iagnosed with AF, leading to an additional 40% reduc-
ion in the risk of recurrent stroke compared with that
chieved with antiplatelet therapy [2—4]. The detection
f arrhythmias associated with a high cardioembolic risk
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EECG detection of paroxysmal AF after ischaemic stroke
after stroke/transient ischaemic attack (TIA) is particularly
important in the management of such patients.
Despite a thorough aetiological workup, around one third
of ischaemic strokes in young patients remain unexplained
[5,6]. Occult paroxysmal AF is a possible cause of crypto-
genic stroke and TIA [7,8] in these patients, as individuals
with paroxysmal AF have the same risk of ischaemic stroke
as those with sustained AF [9,10].
Early diagnosis triggers earlier treatment for secondary
prevention of stroke [11]. In a systematic review of ﬁve
studies, in which the duration of electrocardiogram (ECG)
recording ranged from 24 to 72 hours, the overall rate of
newly detected AF or ﬂutter was 4.6% among consecutive
patients with ischaemic stroke [12]. Current guidelines from
the European Stroke Organization estimate that extending
the duration of monitoring (prolonged event-loop recording)
may improve the rate of detection of paroxysmal AF [13].
Many devices are now available to manage such patients
[14]. However, the feasibility and results of longer mon-
itoring remain conﬂicting: for example, supplementary
paroxysmal AF rates ranging from 5.3% to 20.0% have
been detected in patients with cryptogenic stroke/TIA in
observational studies [8,15—18] versus 0% in one random-
ized study [19]. Most of these studies involved patients
aged≥ 65 years. The value of longer monitoring in younger
patients has been poorly studied, as the rate of paroxysmal
AF in patients with stroke increases with age [20,21].
We aimed to assess the incidence of paroxysmal AF
in unselected patients with stroke aged between 18 and
60 years, using the SpiderFlash® external loop recorder (ELA
Medical, Minneapolis, MN, USA) for 21 days.
Methods
Study design and population
This prospective study consecutively included patients
aged < 60 years admitted to the Neurology Department of
Annecy Hospital with a diagnosis of stroke conﬁrmed on
magnetic resonance imaging (MRI) between February 2011
and July 2012. The diagnosis of stroke required imaging
evidence of cerebral or spinal cord infarction consis-
tent with the presenting neurological syndrome, persistent
neurological deﬁcits attributable to cerebral ischaemia or
conﬁrmed evidence of retinal ischaemia on ophthalmologi-
cal examination [13].
Data were collected on patient demographics, clinical
history, cardiac test results and radiological test results. All
patients underwent 24-hour ECG recording, biological tests,
transthoracic echocardiography and carotid Doppler assess-
ment. Transoesophageal echocardiography and limb venous
Doppler assessment were performed if required.
Patients with a history of AF or any supraventricular
tachycardia, those presenting with AF on the resting ECG
recording and/or on the 24-hour ECG recording, and those
taking antiarrhythmic agents were excluded. Other exclu-
sion criteria were patients with a Rankin score > 4, patients
in whom baseline screening was not completed, patients
not living in the province and those who refused consent.
Patients were classiﬁed into two stroke groups according to
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he results of the stroke evaluation: stroke of known cause
SKC) or cryptogenic stroke (CS).
Patients were advised to undergo monitoring for 21 days;
hey removed and applied the electrodes themselves.
atients were instructed to write in a diary if they had acute
ardiac or neurological symptoms.
evice
he SpiderFlash external loop recorder device was used.
atients wear the SpiderFlash device like a necklace.
his event recorder monitor, coupled with its analyser
ventScopeTM (Sorin Group, Milan, Italy), comprises three
ardiac leads attached to a small pocket-sized recording
evice; continuous two-channel ECG data are recorded.
SpiderFlash is programmed to take 12 automatic recor-
ings daily, but it also takes recordings started by the patient
n the event of symptom onset. SpiderFlash is based on
ecure Datacard technology (Datacard Group, Minnetonka,
N, USA), providing markedly expanded memory capacity.
SpiderFlash can record an ECG for up to 6minutes before
nd 3minutes after arrhythmia detection or patient acti-
ation—as often as is needed. Therefore, an event can be
ecorded even if SpiderFlash is activated after symptom res-
lution (e.g. after a syncopal episode when the patient has
egained consciousness).
The device uses an event detection algorithm well suited
o capturing asymptomatic paroxysmal events, including
ntermittent AF. The event detection algorithm uses RR
nterval variability and QRS morphology analysis to detect
ll possible AF events, which are then transmitted to a physi-
ian for manual review and conﬁrmation, based on standard
iagnostic criteria (absence of P-wave activity and irregular
R interval). In our study, the manual review was done by
ne of two cardiologists specialized in heart rhythm man-
gement who were participating in the study, to conﬁrm the
resence or absence of paroxysmal AF episodes.
utcomes
he primary outcome was the detection of paroxysmal AF
pisodes lasting > 30 seconds on the 21-day recording. The
econdary outcome was the detection of paroxysmal AF
pisodes lasting < 30 seconds and any arrhythmia on the 21-
ay recording.
tatistical analysis
ontinuous variables are expressed as means± standard
eviations or medians± interquartile ranges; categorical
ariables are expressed as percentages. Student’s t-test was
sed for continuous variables and the Chi2 test or Fisher’s
xact test was used for categorical variables. All tests
ere two-sided and P values < 0.05 were considered statis-
ically signiﬁcant. Statistical analysis was performed using
pi InfoTM version 7 (CDC, Atlanta, GA, USA).esults
verall, 56 patients with ischaemic stroke were included;
he mean age was 48± 9 years (range 31—60 years). Thirty-
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ine patients were classiﬁed as having CS and 17 as having
KC. Two CS patients were excluded because of prema-
ure discontinuation of monitoring (Fig. 1). Table 1 shows
he patients’ baseline characteristics; there were signiﬁcant
roportions of obese and diabetic patients in the SKC group.
An ECG recording, transthoracic echocardiography and
erebral MRI were completed in all patients. Overall, 7% of
atients had a dilated left atrium, deﬁned as a left atrium
urface > 20 cm2. None of the patients had mitral stenosis,
1% had cortical stroke and 25% had multiple infarcts in a
ingle territory, without any signiﬁcant difference between
he two groups (Table 2).
ardiac monitoring results
utpatient monitoring began a median of 34 days (interquar-
ile range 22—57 days) after symptom onset, and mean
uration of monitoring was 20± 3 days (Table 2). Mon-
toring was discontinued prematurely in 2 of 56 (4%)
atients.
1
o
c
igure 1. Study ﬂow chart: period of inclusion, February 2011 to JulyK. Yayehd et al.
One patient (1 of 54 [2%], 95% conﬁdence interval [CI]
.05—10) had a paroxysmal AF episode lasting > 30 seconds
1 of 37 [3%] CS patients vs 0 of 17 SKC patients); this event
ccurred in a 37-year-old man presenting with recurrent
troke, who had migraine with aura, no cardiovascular risk
actors, no dilatation of the left atrium and preserved left
entricular ejection fraction (Table 3).
One patient (1 of 54 [2%], 95% CI 0.05—10) had a brief
aroxysmal AF episode lasting < 30 seconds (1 of 37 [3%] CS
atients vs 0 of 17 SKC patients); this event occurred in a
2-year-old man with recurrent stroke but no cardiovascular
isk factors (Table 3).
No patients presented with symptoms and none activated
recording by the SpiderFlash monitor (i.e. there were no
atient-triggered recordings). All paroxysmal AF episodes
ere asymptomatic.
Two CS patients and one SKC patient (3 of 54 [6%], 95% CI
.2—15.4) presented numerous premature atrial complexes.
Non-sustained ventricular tachycardia was detected in 1
f 37 CS patients (3%) and numerous premature ventricular
omplexes were detected in 1 of 17 SKC patients (6%).
2012. AF: atrial ﬁbrillation; TIA: transient ischaemic attack.
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Table 1 Patient baseline characteristics.
Characteristics Total(n = 56) CS group(n = 39) SKC group(n = 17) Pa
Age (years) 48± 9 47± 8 51± 9 0.16
Women 21 (38) 15 (38) 6 (35) 0.82
White ethnicity 56 (100) 39 (100) 17 (100)
BMI > 25 kg/m2 8 (14) 3 (8) 5 (29) 0.046
Hypertension 15 (27) 8 (20.5) 7 (41) 0.11
Diabetes mellitus 4 (7) 1 (3) 3 (18) 0.045
Hyperlipidaemia 16 (29) 9 (23) 7 (41) 0.17
Current smoker 20 (37) 12 (31) 8 (47) 0.24
Coronary artery disease 3 (5) 1 (3) 2 (12) 0.21
Cardiovascular diseaseb 3 (5) 3 (8) 0 (0)
History of TIA/stroke 3 (5) 3 (8) 0 (0) 0.32
NHISS 2 (0—6) 2 (0—6) 3.5 (1—7) 0.94
Positive AIDS test 1 (2) 1 (3) 0 (0) 0.78
uTSH 1.5 (0.9) 1.6 (0.9) 1.3 (0.8) 0.30
HbA1C 5.9 (1.6) 5.6 (0.9) 6.4 (2.5) 0.11
LDL-C (mg/L) 124 (47) 127 (49) 117 (43) 0.51
Obstructive sleep apnoea 1 (2) 0 (0) 1 (6) 0.30
Migraine 5 (9) 4 (10) 1 (6) 0.52
Data are mean± standard deviation, number (%) or median (interquartile range). AIDS: acquired immune deﬁciency syndrome; BMI:
body mass index; CS: cryptogenic stroke; HbA1C: glycosylated haemoglobin; LDL-C: low-density lipoprotein cholesterol; NHISS: National
Health Institute Scale Score; SKC: stroke of known cause; TIA: transient ischaemic attack; uTSH: ultrasensitive thyroid stimulating
hormone.
a CS versus SKC.
b One interatrial communication, one ventricular septal defect and one hypertrophic cardiomyopathy.
pDiscussionThis study showed a lower than expected rate of paroxys-
mal AF with 21-day cardiac monitoring in young patients
r
m
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Table 2 Test information and results.
T
Start of outpatient monitoring after symptom onset (days) 3
Duration of monitoring (days) 2
Transoesophageal echocardiography 4
Limb venous Doppler assessment 5
Left atrial diameter (mm) 3
Left atrial enlargementb 4
Left ventricular ejection fraction (%) 6
Infarct classiﬁcation
Subcortical non-lacunar 2
Cortical 3
Infarct distribution
Anterior territory 4
Posterior territory 7
Anterior and posterior infarct 4
Multiple vascular territories 7
Multiple infarcts, single territory 1
Extended infarct 2
Data are median (interquartile range), mean± standard deviation or n
a CS versus SKC.
b Left atrium surface > 20 cm2.resenting with ischaemic stroke, compared with the results
eported in several observational studies with long cardiac
onitoring [8,16,17,22,23]. Many reasons may explain this
iscrepancy.
otal(n = 56) CS group(n = 39) SKC group(n = 17) Pa
4 (22—57) 35 (20—67) 32 (23—56) 0.08
0± 3 21± 3 20± 3 0.57
7 (84) 35 (90) 12 (71) 0.08
1 (91) 35 (90) 16 (94) 0.60
4± 6 33± 6 37± 4 0.05
(7) 3 (8) 1 (6) 1.00
5± 7 64± 8 68± 7 0.32
2 (39) 14 (36) 8 (47) 0.19
4 (61) 27 (69) 7 (41)
5 (80) 34 (87) 11 (65) 0.07
(13) 3 (8) 4 (24) —
(7) 4 (10) 0 (0) —
(12.5) 6 (15) 1 (6) 0.42
4 (25) 10 (25.4) 4 (24) 1.00
(4) 2 (5) 0 (0) 0.50
umber (%). CS: cryptogenic stroke; SKC: stroke of known cause.
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Table 3 Characteristics of paroxysmal atrial ﬁbrillation episodes.
PAF > 30 seconds PAF < 30 seconds
Patient’s study group CS CS
Age (years); sex 37; male 52; male
Cardiovascular risk factors
BMI (kg/m2) 23.5 24.8
Hypertension No No
Tobacco use No No
Diabetes No No
Cardiovascular disease No No
Left atrial surface (cm2) 19 18
LVEF (%) 60 70
Clinical presentation Recurrent stroke Recurrent stroke
Number of PAF episodes 4 1
Longest PAF episode (seconds) 55 2
Delay of occurrence of ﬁrst PAF episode (days) 6 20
Total PAF burden recorded (seconds) 172 2
BMI: body mass index; CS: cryptogenic stroke; LVEF: left ventricular ejection fraction; PAF: paroxysmal atrial ﬁbrillation.
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sThe low rate of paroxysmal AF in our study could be
ue to the characteristics of our sample, which comprised
oung patients with few cardiovascular risk factors, low
ates of cardiac diseases and few cases of left atrial dilata-
ion. In comparison, two retrospective studies, reported by
iller et al. [23] and Elijovich et al. [16], which included
lder patients with more heart failure events, detected
ates of paroxysmal AF during long cardiac monitoring of
7% and 20%, respectively, among patients with cryptogenic
troke. Two prospective registries with consecutive inclu-
ion of patients with cryptogenic stroke/TIA found similar
esults [8,16,22]. The relationship between paroxysmal AF
nd age is strong, as shown in the report by Rabinstein
t al. [24]; among 132 patients presenting with stroke, the
t
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Table 4 Cryptogenic stroke characteristics in the present stu
Present
study
(n = 39)
Miller et al.
[19]
(n = 156)
E
e
(
Type of study Consecutive
series
Retrospective R
Age (years) 47± 8 68.5± 11 6
Women 39 50 6
Hypertension 21 87 7
Diabetes 3 42 3
Hyperlipidaemia 23 63 5
CHD 3 24 1
Heart failure 5 8 n
Tobacco use 26 21 5
TIA 0 21 3
Left atrial enlargement 8 n/a 2
Cortical infarcts on MRI 69 26.4 n
Duration of recording (days) 20.3± 2.8 21 (1—30) 3
Rates of PAF detected 3 17.3 2
Data are mean± standard deviation, median (interquartile range) or %
n/a: not available; PAF: paroxysmal atrial ﬁbrillation; TIA: transient isuthors found signiﬁcantly more paroxysmal AF events in
atients aged≥ 65 years, irrespective of whether they had
S or SKC [24]. Many other studies enrolled only patients
ged≥ 65 years, to check the occurrence of paroxysmal
F events after ischaemic stroke [25,26]. Kamel et al.,
owever, in a recent randomized study comparing wear-
ng and not wearing a cardiac monitor after stroke, showed
hat detected rates of AF were lower than expected (0%)
mong patients with a mean age of 67 years. The authors
uggested that this might have been due to chance and
he study’s lack of power to determine clinical outcomes
only 15 patients wore the CardioNet Mobile Cardiac Out-
atient Telemetry device; CardioNet, Malvern PA, USA)
Table 4).
dy and in other studies.
lijovich
t al. [16]
n = 36)
Flint et al.
[22]
(n = 239)
Tayal et al.
[8]
(n = 56)
Kamel
et al. [19]
(n = 40)
etrospective Consecutive
series
Consecutive
series
Randomized
5± 15 65± 14 66± 11 67± 12
0 40 49 43
5 66 77 73
5 15 16 25
0 91 75 45
5 11 14 5
/a 5 2 3
n/a 36 25
8 0 14 33
5 n/a 15 43
/a n/a 85 64
0 24.5± 8.7 21 (5—21) 21
0 11.5 23 0
. CHD: coronary heart disease; MRI: magnetic resonance imaging;
chaemic attack.
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In our study, outpatient monitoring started 34 days
(mean) after the stroke event; this duration might be too
long, as the pilot randomized trial by Kamel et al., which
began monitoring 22 days after the events, also did not reg-
ister any episodes of paroxysmal AF. The mechanism that
links AF and stroke is still not fully understood. AF may
lead to mechanical atrial dysfunction and subsequent throm-
bus formation and dislodgement—a hypothesis supported by
the high thromboembolic rate following cardioversion in the
absence of anticoagulation [27]. In that setting, the duration
and timing of AF determine the risk of stroke, and AF occurs
immediately before the thromboembolic event. Thus, mon-
itoring after an embolic event may underdetect AF [24].
The SpiderFlash monitor was worn for 21 days in our
study, which is a similar duration to that in other stud-
ies; the CardioNet Mobile Cardiac Outpatient Telemetry
was worn for 21—30 days, for example [8,16,19,23]. How-
ever, this duration might be too short. By comparison, in
the Asymptomatic Atrial Fibrillation and Stroke Evaluation
in Pacemaker Patients and the Atrial Fibrillation Reduc-
tion Atrial Pacing Trial (ASSERT) study, which enrolled 2580
hypertensive patients aged≥ 65 years with an implantable
device and no history of AF, subclinical atrial tachyarrhyth-
mias occurred in 36% of patients over a mean follow-up of
2.8 years and were associated with a 2.5-fold increase in the
risk of stroke or systemic embolism [26]. Rabinstein et al.
suggested that very prolonged monitoring may be necessary
to identify patients at risk of stroke from paroxysmal AF [24].
This was also the ﬁnding of the Relationship Between Daily
Atrial Tachyarrhythmia Burden From Implantable Device
Diagnostics and Stroke Risk Study (TRENDS), which showed
that 73% of patients with thromboembolic events during the
monitoring period had no atrial tachyarrhythmias detected
by the implantable device over the 30 days that preceded
the event [25].
Further randomized trials will be needed to clarify the
best non-invasive cardiac test to detect paroxysmal AF after
cryptogenic stroke. In this setting, the current randomized
Event Monitor Belt for Recording Atrial Fibrillation After
a Cerebral Ischemic Event (EMBRACE) trial is comparing a
repeated standard 24-hour Holter monitor strategy with a
30-day ambulatory cardiac event monitor strategy (using
the AccuHeart Electrode Belt, Braemar ER 910AF monitor;
Braemar Inc., Eagan, MN, USA) (NCT00846924).
As the ASSERT [26] and TRENDS [25] studies found signif-
icant rates of paroxysmal AF using implantable devices, the
question of the best method for detecting this arrhythmia
remains relevant: non-invasive or invasive cardiac monitor-
ing? No patient presented with symptoms in the present
study, which is a common ﬁnding; many studies, such as
the XPECT [28] and TRENDS [25] studies, found several
asymptomatic paroxysmal AF episodes after a stroke event
[24,28,29]. Brief paroxysmal AF episodes (< 30 seconds) are
also common, but the prognostic value and relevance of
treating such brief events are still debated [25,26] as no
randomized study has been conducted to establish whether
there is a difference in the prevalence of brief episodes of
AF in patients with and without stroke. The ongoing CRYpto-
genic STroke And underlying Atrial Fibrillation (CRYSTAL-AF)
trial, which is comparing the incidence of AF detection using
the REVEAL XT cardiac monitor (Medtronic, Minneapolis, MN,
USA) with routine monitoring in patients with cryptogenic195
troke or TIA [30], and the EMBRACE study, are expected to
rovide some answers to these questions.
Patients with SKC had a signiﬁcantly higher body mass
ndex and a higher prevalence of diabetes. However, we
ecorded no cases of AF in this group, probably because
hey had a cause of stroke other than AF. We also recorded
o ventricular arrhythmia in this group because the Spider-
lash monitors were programmed to prioritize recordings of
trial arrhythmia in their memory. On the other hand, these
atients had cardiovascular risk factors, but their left ven-
ricular ejection fractions were normal, and therefore, they
ere at low risk of ventricular arrhythmias.
Our study was limited by the small number of patients;
onsequently, these preliminary ﬁndings require conﬁrma-
ion in a larger study.
onclusion
his prospective observational study detected a low rate of
aroxysmal AF with 21-day cardiac monitoring among young
atients presenting with ischaemic stroke. This result high-
ights the need to identify patients who would beneﬁt from
uch long monitoring. Further larger studies are needed to
etermine the relevance of longer monitoring among young
atients.
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